SCHEMBL5607979

SCHEMBL5607979

Cc1nc(NC(=O)O)sc1C(=O)N(C)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.56
ALDH1A1 P00352 5/20 0.52
NPC1 O15118 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
HPGD P15428 3/20 0.50
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
POLB P06746 3/20 0.49
HTT P42858 2/20 0.49
TP53 P04637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
ALOX5 P09917 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773361 0.85 LCK (0.59) RAB9AALDH1A1NPC1SMN1; SMN2HPGD
SCHEMBL19229754 0.83 ALDH1A1 (0.47) RAB9AALDH1A1NPC1SMN1; SMN2HPGD
SCHEMBL774683 0.80 LCK (0.52) RAB9AALDH1A1NPC1SMN1; SMN2POLB
SCHEMBL774205 0.75 MAPT (0.81) RAB9AALDH1A1NPC1SMN1; SMN2HPGD
SCHEMBL4606198 0.74 ALDH1A1 (0.63) RAB9AALDH1A1NPC1SMN1; SMN2HPGD
SCHEMBL774466 0.74 LCK (0.71) RAB9ANPC1MAPT
SCHEMBL4393473 0.73 RXFP1 (0.53) RAB9AALDH1A1NPC1SMN1; SMN2HPGD
SCHEMBL3580881 0.73 POLB (0.63) RAB9AALDH1A1NPC1SMN1; SMN2HPGD
SCHEMBL19229755 0.73 HTR2C (0.42) RAB9ANPC1SMN1; SMN2HPGDKDM4E
SCHEMBL5607983 0.72 CHRNA7 (0.60) RAB9AALDH1A1NPC1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758564-A2 SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER Brystol-Myers Squibb Company (US) 2007-03-07 EP disclosed
WO-2005094376-A2 SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-13 WO disclosed